Price history
¥303Latest-57.9%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview
Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
News
Key numbersShowing 8 of 19
PER
11.62How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.PBR
0.88How many times the company's net assets? Around 1x is generally considered a benchmark.ROE
-10.7%Earning power. A figure above 10% is generally considered good.Dividend yield
0.0%The annual dividend as a percentage of the share price.Market capitalization
¥2.0bnShare price × number of shares. The value of the entire company.Equity ratio
67.7%The proportion of assets funded by money that does not have to be repaid.Operating margin
-80.7%The percentage of revenue remaining from the company’s core business.Revenue growth (3 years)
-4.0%The average annual growth in sales over the past three years.What to watch next
Specific measures and progress disclosures for the medium- to long-term five-year revision, “Ivy creates Japanese skin,” including a fundamental overhaul of the product portfolio and sales structure
2026 onward (plan launch)Impact HighLikelihood Medium
Core-product shipment volumes and achievement of targets, particularly quantitative confirmation that the “shipment shortfalls” for Red Power Serum and White Power Serum have been resolved
Quarterly to annual results from the next fiscal period onwardImpact HighLikelihood Medium
Expansion of exports to Taiwan, including increased local sales of Stem Signal
2026 onwardImpact MediumLikelihood Medium
Specific progress toward the commercialization or licensing of R&D and IP assets, including NRF2 activators, MAO inhibitors and TGF-β signaling inhibitors
Medium term (uncertain)Impact MediumLikelihood Low
Assessment of the accounting impact from preparations for, and the commencement of, adoption of the new lease accounting standard
Fiscal year ending March 2028Impact LowLikelihood Medium
What to watch next
Who owns itTop holders total 34.9%
Listed holders 34.9%Everyone else 65.1%
株式会社白銀社16.92%
株式会社ブリーズ3.34%
アイビー化粧品 Business Partner Shareholding Association2.42%
安藤 英基2.14%
Shirogane Emiko (白銀 恵美子)1.89%
安藤 英雄1.80%
Shirogane Koji (白銀 浩二)1.73%
アイビー共栄会1.69%
2 other listed holders2.97%
| Holder | Ownership (%) |
|---|---|
| 株式会社白銀社 | 16.92 |
| 株式会社ブリーズ | 3.34 |
| アイビー化粧品 Business Partner Shareholding Association | 2.42 |
| 安藤 英基 | 2.14 |
| Shirogane Emiko (白銀 恵美子) | 1.89 |
| 安藤 英雄 | 1.80 |
| Shirogane Koji (白銀 浩二) | 1.73 |
| アイビー共栄会 | 1.69 |
| 2 other listed holders | 2.97 |
This company's documents
Timely disclosures
- 2026-10-16Notice Regarding Personnel Changes
- 2026-10-08Notice of Revision to Earnings Forecast
- 2026-09-29Notice Regarding the Filing of a Lawsuit Against Kao Corporation
- 2026-09-24Notice of Research Presentations at the 72nd Annual Meeting of the Japanese Society of Pharmacognosy
- 2026-08-21Notice of Completion of Payment for the Issuance of the Sixth Series of Stock Acquisition Rights by Third-Party Allotment (with Rights to Convert into Stock Acquisition Rights with an Adjustable Exercise Price)
- 2026-08-05Notice regarding the issuance of the 6th series of stock acquisition rights by way of a third-party allotment, with rights to convert into stock acquisition rights with an exercise price adjustment feature
- 2026-08-05Notice Regarding the Acquisition and Cancellation of Class A Preferred Shares
- 2026-08-05Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-Consolidated)
45 more
- 2026-08-05Notice Regarding a Change in the Scheduled Expenditure Period for the Fifth Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause)
- 2026-07-23Notice of Research Presentation at the 47th Annual Meeting of the Japanese Society of Inflammation and Regeneration
- 2026-07-02Notice of Research Presentations at the 30th Annual Meeting of the Japanese Association of Molecular Targeted Therapy for Cancer
- 2026-07-01Notice Regarding the Escalation of Tensions in the Middle East (Update 2) and Revisions to Earnings Forecasts
- 2026-06-16Notice Regarding the Impact of Heightened Tensions in the Middle East (Follow-up)
- 2026-06-0451st Annual General Meeting of Shareholders of IVY COSMETICS CORPORATION: Matters Not Included in the Documents Delivered
- 2026-06-04Notice of Convocation of the 51st Annual General Meeting of Shareholders_Ivy Cosmetics
- 2026-05-20Notice Regarding Tentative Executive Appointments and Personnel Changes
- 2026-05-20Notice Regarding a Reduction in the Amounts of Capital and Capital Reserves
- 2026-05-20Notice Regarding Dividend from Retained Earnings
- 2026-05-14Summary of Financial Results for the Fiscal Year Ending March 2026 (Japanese GAAP) (Non-consolidated)
- 2026-05-14Notice Regarding the Impact of Escalating Tensions in the Middle East and Earnings Forecasts for the Fiscal Year Ending March 2027
- 2026-05-14Notice Concerning Dividend of Surplus on Preferred Shares
- 2026-05-13Notice of Revision to Earnings Forecast
- 2026-03-30Notice of a Research Presentation at the 146th Annual Meeting of the Pharmaceutical Society of Japan (3)
- 2026-03-30Notice of Research Presentation at the 146th Annual Meeting of the Pharmaceutical Society of Japan (2)
- 2026-03-27Notice of Research Presentations at the 146th Annual Meeting of the Pharmaceutical Society of Japan (1)
- 2026-03-25Notice Regarding Organizational Changes and Personnel Changes
- 2026-03-18Notice of Research Presentation at the 106th Annual Meeting of the Chemical Society of Japan
- 2026-03-17第99回日本薬理学会年会における研究発表のお知らせ
- 2026-02-18第三者割当による第5回新株予約権(行使価額修正条項付)の行使完了および月間行使状況に関するお知らせ
- 2026-02-10令和8年3月期 第3四半期決算短信〔日本基準〕(非連結)
- 2026-02-02Notice Concerning the Monthly Exercise Status of the Fifth Series of Stock Acquisition Rights through a Third-Party Allotment with Exercise Price Adjustment Provisions
- 2026-01-05Notice Concerning the Monthly Exercise Status of the Fifth Series of Stock Acquisition Rights through a Third-Party Allotment with Exercise Price Adjustment Provisions
- 2025-12-09Notice Regarding Personnel Changes
- 2025-12-05第48回日本分子生物学会年会における研究発表について(2)
- 2025-12-05第48回日本分子生物学会年会における研究発表について(1)
- 2025-12-01Notice Concerning the Monthly Exercise Status of the Fifth Series of Stock Acquisition Rights through a Third-Party Allotment with Exercise Price Adjustment Provisions
- 2025-11-11令和8年3月期 第2四半期(中間期)決算短信〔日本基準〕(非連結)
- 2025-11-04第98回日本生化学会大会における研究発表について
- 2025-11-04Notice Concerning the Monthly Exercise Status of the Fifth Series of Stock Acquisition Rights through a Third-Party Allotment with Exercise Price Adjustment Provisions
- 2025-09-30Notice Concerning the Monthly Exercise Status of the Fifth Series of Stock Acquisition Rights through a Third-Party Allotment with Exercise Price Adjustment Provisions
- 2025-09-30第84回日本癌学会学術総会における研究発表について
- 2025-09-30Notice Regarding Personnel Changes
- 2025-09-24第三者割当による第5回新株予約権(行使価額修正条項付)の大量行使に関するお知らせ
- 2025-09-22Notice of Revision to Earnings Forecast
- 2025-09-16日本生薬学会第71回年会における研究発表のお知らせ
- 2025-09-12第67回天然有機化合物討論会における研究発表のお知らせ
- 2025-09-01Notice Concerning the Monthly Exercise Status of the Fifth Series of Stock Acquisition Rights through a Third-Party Allotment with Exercise Price Adjustment Provisions
- 2025-08-06令和8年3月期 第1四半期決算短信〔日本基準〕(非連結)
- 2025-07-23第54回医用高分子シンポジウムにおける研究発表のお知らせ
- 2025-07-04Notice Regarding Personnel Changes
- 2025-07-01Notice Concerning Dividend of Surplus on Preferred Shares
- 2025-07-01Notice of Changes in Officers' Positions
- 2025-07-01Notice Concerning the Monthly Exercise Status of the Fifth Series of Stock Acquisition Rights through a Third-Party Allotment with Exercise Price Adjustment Provisions
Threads
- 2026-10-08Building a High-Performance Product Portfolio Centered on Serums
- 2026-10-08Discontinuation of raw material and supply deliveries, quality issues, and changes in laws and regulations
- 2026-09-29Protecting the value of the “BASIC+” brand and enforcing intellectual property rights
- 2026-09-24Continued Research into Skin Whitening, Anti-Aging, New Materials and DDS
- 2026-08-21Raising funds to develop high-performance cosmetics through the Sixth Stock Acquisition Rights
- 2026-08-05Developing Core Sales Staff and Strengthening the Training System
- 2026-08-05Balancing Retained Earnings with High Shareholder Returns
- 2026-08-05Launch of the Food with Function Claims Product “GABA Balance” and Expansion of Sales in the Health Food Market
75 more
- 2026-08-05Creating 100,000 loyal users with distributors
- 2026-08-05Policy Not to Exercise the Acquisition Clause for Class A Preferred Shares
- 2026-08-05Advancing Sustainability as a Key Management Priority
- 2026-08-05Environmentally Friendly Products and Materials and Sustainability Indicators through 2030
- 2026-08-05The Theme of Eternal Beauty: “Normalizing”
- 2026-08-05Enhancing dividend resources through reductions in reserves and general reserve
- 2026-08-05Five-Year Overhaul of the Sales System, Beauty Education Framework and Product Framework
- 2026-07-01Significant Revenue Growth This Fiscal Year and Launch of a Major Skincare Series
- 2026-06-23Expansion of Distributors and Sales Offices and Support for Sales Organizations
- 2026-06-23Strengthening the earnings base through lower manufacturing costs, minimized fixed costs, and effective use of assets
- 2026-06-23Maturity of the Domestic Cosmetics Market, Population Decline and Intensifying Competition
- 2026-06-23Financial Condition of Sales Organizations and Sharp Changes in Channel Inventory
- 2026-06-23Dependence on New and Enhanced Products and Seasonal Fluctuations in Sales and Profit
- 2026-06-23Country Risk, Foreign-Exchange Fluctuations, and Investment Recovery in Overseas Businesses
- 2026-06-23Operation of Risk Management, Internal Audits, Whistleblowing, and ISO Audits
- 2026-06-23Raising Working Capital through Bank-Guaranteed Privately Placed Bonds
- 2026-06-23Employee Growth and Sustained High Levels
- 2026-06-23Increase in Trade Receivables and Negative Cash Flow from Operating Activities
- 2026-06-23Increase in cosmetics production and sales results
- 2026-06-23Achieving ¥40 billion in sales at retail prices and No. 1 status in the direct-sales cosmetics industry
- 2026-06-23Sales and Payment App and Web-Based Sales Organization Communications Platform
- 2026-06-23Rebuilding a Simple, Easy-to-Sell Product Lineup and Production Management System
- 2026-06-23Performance-linked incentives through an employee share delivery trust
- 2026-06-23Performance-Linked Share-Based Compensation Plan for Directors
- 2026-06-23Improving Deteriorated KPIs and Operating Cash Flow
- 2026-06-23Difficulty securing door-to-door sales representatives
- 2026-06-23Increase in Inventories and Lengthening of the Inventory Turnover Period
- 2026-06-23Deterioration in Operating Cash Flow and Decline in Cash Liquidity
- 2026-06-23Risk of long-term borrowings becoming immediately due and payable due to covenant breach
- 2026-06-23Deterioration in performance due to fixed-cost and expense leverage when sales decline
- 2026-06-23Raising Funds for New Product Development and Marketing through a Third-Party Allotment of Stock Acquisition Rights
- 2026-06-23Raising the Percentage of Female Officers to 30% and the Percentage of Female Managers to 35%
- 2026-06-23Generating overseas sales and other revenue outside the door-to-door sales business
- 2026-06-23Transition to a Performance-Linked Personnel System
- 2026-06-23Compliance with and risk of failing to meet the Tokyo Stock Exchange Standard Market’s continued listing criteria
- 2026-06-23Guarantees of Customers’ Debt
- 2026-06-04Retaining existing customers, acquiring new customers, and strengthening counseling-based sales
- 2026-06-04Management oversight by outside directors and outside audit and supervisory board members
- 2026-06-04Financial Soundness and Management Consulting Support for Sales Companies
- 2026-06-04Objectivity and Transparency in the Executive Compensation Decision-Making Process Through the Compensation Committee
- 2026-06-04Application of the Revenue Recognition Accounting Standard and Changes in the Presentation of Sales Rebates
- 2026-06-04Industrial Applications of Patented Technology
- 2026-03-25Accelerating Management Decision-Making and Clarifying Responsibility and Authority
- 2026-03-25Review of Sales Locations Following Reorganization of the Sales Division
- 2025-11-14Higher revenue and profits for the fiscal year ended March 2016
- 2025-11-14Downside Risks to Economic Conditions from Policy Effectiveness, Overseas Economic Conditions, and Financial-Market Volatility
- 2025-11-14Significant Doubt Regarding Going Concern and Remedial Measures
- 2025-11-14Impact of COVID-19 on Sales Activities and Demand
- 2025-06-30A business model centered on door-to-door and face-to-face sales
- 2025-06-30The Practice and Pursuit of Love, Beauty and Abundance, and a Wonderful Company
- 2025-06-30Company-Wide Management through Management, Budget Control and Sales Strategy Meetings
- 2025-06-30Pursuit of Product Quality Based on Safety and Usefulness Evaluations
- 2025-06-30Realizing an Only One: A Leading Beauty Company
- 2025-06-30Regionally Rooted Face-to-Face Sales and Support Activities
- 2025-06-30Risk to the door-to-door sales framework from amendments to the Act on Specified Commercial Transactions and related laws
- 2025-06-30Termination of Retirement Benefit Plan and Recognition of Extraordinary Loss
- 2023-11-14Flexible Capital Policy Through Share Repurchases
- 2023-06-30Business alliance that avoids cannibalization of the door-to-door sales business
- 2022-06-30Transition to Non-Consolidated Financial Reporting Following the Liquidation of アイプラティナ
- 2022-06-30Transfer to the Tokyo Stock Exchange Standard Market
- 2022-06-30Reorganization of Oversight and Decision-Making Frameworks through Transition to a Company with an Audit and Supervisory Committee
- 2021-06-30Policy of Generally Not Holding Cross-Shareholdings
- 2021-06-30Management targeting an ROIC of 10–20% based on a WACC assumption of 8%
- 2021-06-30Cross-Border Logistics System for Mainland China Using WeChat
- 2021-02-12¥4.25 billion in net sales and profit targets for the fiscal year ending March 2020
- 2019-06-28PR Strategy for Expanding Contact Points with Sales Organizations and External Stakeholders
- 2019-02-14Amendment to the Articles of Incorporation to Authorize the Issuance of Class A Preferred Shares
- 2018-11-14Exploring a Direct-to-Consumer Cosmetics Business Outside Door-to-Door Sales
- 2018-11-14Test Marketing and Monetization Risk for the アイプラティナ Service
- 2018-11-14アイプラティナ’s Excess Liabilities
- 2018-06-292017 Corporate Theme: “Happy”
- 2018-06-29Achievement of ¥5.7 billion in net sales, operating profit and other targets for FY2018
- 2017-06-30Corporate Theme for 2016: “With”
- 2017-06-30Expanding the Customer Base in Taiwan
- 2017-06-30Review of the Share Trading Framework through a Share Consolidation and Change in the Number of Shares Constituting One Trading Unit